LGD-4033

LGD-4033, also known as Ligandrol, is a selective androgen receptor modulator (SARM) currently under investigation as a pharmaceutical treatment for muscle loss and age-related weakness. However, LGD-4033 has not been approved by the United States Food and Drug Administration (FDA) for clinical use in humans. Here are five crucial things to know about this unapproved SARM:

What is LGD-4033?

LGD-4033 is a SARM that selectively interacts with androgen receptors.

Currently, LGD-4033 is being investigated as a pharmaceutical treatment for muscle loss and age-related weakness.

However, LGD-4033 has not received FDA approval for clinical use in humans.

Is LGD-4033 Banned on the World Anti-Doping Agency (WADA) Prohibited List?

Yes, LGD-4033 is included in the S1.2 Other Anabolic Agents category on the WADA Prohibited List.

LGD-4033, along with all SARMs, is prohibited for all athletes, both in and out of competition.

How Does LGD-4033 Enhance Performance?

LGD-4033 has been shown to increase muscle mass without significant androgenic effects.

Some athletes may misuse LGD-4033 due to its potent anabolic effects.

What are the Health Risks of LGD-4033 Use?

In addition to the risk of positive test results, the short-term and long-term effects of LGD-4033 are not fully understood.

LGD-4033 may disrupt hormonal signals in the body by reducing testosterone and other hormone production.

Can Therapeutic Use Exemption (TUE) be Granted for LGD-4033?

No, because LGD-4033 is an investigational drug and has not received medical approval from the FDA.

Remember that the use of LGD-4033 is not medically approved and carries potential risks. Always consult with a healthcare professional before using this medication.